The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
Identity verified. The target is human CD86, also called B7-2, B70 and CD28LG2 (UniProt P42081), not the related ligand CD80/B7-1. An early human-cell study established that antibodies recognizing CD86 also recognized B70/B7-2 expressed by transfected cells. A later structural study explicitly used the human CD86 sequence assigned to P42081. Its extracellular immunoglobulin-like architecture matches the specified IgV-domain annotation. UniProt record; Caux et al., Journal of Experimental Medicine, November 1994, DOI: 10.1084/jem.180.5.1841; Lankipalli et al., Protein Science, 2021, DOI: 10.1002/pro.4151. (caux1994b70b72isidentical pages 1-2, lankipalli2021crypticassociationof pages 4-5)
CD86 is a cell-surface, single-pass type-I membrane glycoprotein and intercellular signaling ligand, not an enzyme, transporter or peptide-presenting MHC molecule. Its membrane-distal extracellular IgV-like domain mediates recognition of the T-cell receptors CD28 and CTLA-4 (CD152); a membrane-proximal IgC-like domain separates that binding region from the plasma membrane. A transmembrane segment anchors CD86, and a cytoplasmic tail lies inside the expressing cell. Thus, its principal physiological activity occurs outside the cell at the antigen-presenting-cell (APC)–T-cell contact, particularly the immunological synapse. Crystal analysis of the human IgV domain reached 1.90 Å resolution (PDB 5YXK), supporting the domain assignment; proposed zipper-like higher-order assemblies are less securely established as a native human-cell mechanism than the receptor-binding function itself. Lankipalli et al., 2021, DOI: 10.1002/pro.4151. (lankipalli2021crypticassociationof pages 2-4, lankipalli2021crypticassociationof pages 1-2, lankipalli2021crypticassociationof pages 4-5)
CD28 engagement provides the activating “second signal.” When a T-cell receptor recognizes peptide–MHC on an APC, APC-displayed CD86 can bind T-cell CD28 and reinforce T-cell activation, including IL-2 production and proliferation. The relevant intracellular activation pathways—among them PI3K–AKT and transcriptional responses—are principally downstream of CD28 in the T cell; they should not be annotated as catalytic reactions performed by CD86. Human dendritic/Langerhans-cell experiments directly support this ligand function: anti-CD86 reduced the alloreactive T-cell response by 70% in that assay, combined anti-CD80/anti-CD86 blockade reduced it by more than 90%, and anti-CD28 inhibited the response in 9 of 11 tests. These are results of a specific in-vitro alloreaction, not population-wide effect estimates. Caux et al., 1994, DOI: 10.1084/jem.180.5.1841; Lotze et al., Nature Reviews Immunology, 2024, DOI: 10.1038/s41577-024-01061-1. (caux1994b70b72isidentical pages 1-2, lotze2024cd28costimulationnovel pages 1-3)
CTLA-4 engagement makes the same surface ligand available to a counter-regulatory pathway. CTLA-4 competes with CD28 for CD86 and can remove CD86 from APC surfaces, thereby reducing the ligand available for subsequent CD28 costimulation. Human-cell and experimental-model work established CTLA-4-dependent trans-endocytosis of CD80 and CD86. A 2022 mechanistic study found that, after CD86 uptake, CD86 dissociates from CTLA-4 in acidic compartments and CTLA-4 can recycle for further ligand capture; CD80 more readily remains associated and accompanies CTLA-4 toward degradation. Qureshi et al., Science, April 2011, DOI: 10.1126/science.1202947; Kennedy et al., Nature Immunology, August 2022, DOI: 10.1038/s41590-022-01289-w. (qureshi2011transendocytosisofcd80 pages 2-4, kennedy2022differencesincd80 pages 1-2)
A 2023 refinement identifies another route by which CD86 can move between cells: in human T-cell/APC systems, CD28-dependent capture of APC membrane material can place CD86 on the T-cell surface, after which CTLA-4 removes acquired or endogenously expressed B7 ligands by cis-endocytosis. Direct trans-endocytosis and CD28-associated membrane capture followed by cis-endocytosis are distinct experimental mechanisms; neither result warrants describing CD86 itself as an endocytic enzyme. Xu et al., Journal of Experimental Medicine, 2023, DOI: 10.1084/jem.20221391. (xu2023ctla4depletest pages 2-4, xu2023ctla4depletest pages 4-6, xu2023ctla4depletest pages 1-2)
CD86 is present on professional APCs, notably dendritic cells, monocytes/macrophages and activated B cells. Human monocytes and dendritic cells can display it before strong activation, while activation can increase surface availability; expression therefore depends on cell state and should not be read as an unqualified measure of functional T-cell priming. On the expressing cell, its cytoplasmic tail and transmembrane segment govern trafficking rather than substituting for its extracellular receptor-binding function. Jeannin et al., Immunity, September 2000, DOI: 10.1016/S1074-7613(00)00030-3; Bandola-Simon and Roche, Current Opinion in Immunology, June 2023, DOI: 10.1016/j.coi.2023.102325. (jeannin2000solublecd86is pages 1-2, bandolasimon2023regulationofmhc pages 1-2)
One defined surface-control mechanism is MARCH1-dependent ubiquitination: this E3 ligase promotes CD86 removal and degradation, whereas reduced MARCH1 activity during APC maturation favors surface persistence. Mutational analysis of human CD86 identified Pro254 in its transmembrane region as particularly important for recognition by human MARCH1. A Kaposi-sarcoma-herpesvirus ligase, MIR2, also downregulates CD86 but uses a different recognition determinant, centered on extracellular juxtamembrane Asp244. This identifies CD86 as the substrate of ubiquitin-dependent regulation, not as the ubiquitin ligase. Trenker et al., Journal of Biological Chemistry, 2021, DOI: 10.1016/j.jbc.2021.100900; Bandola-Simon and Roche, 2023, DOI: 10.1016/j.coi.2023.102325. (trenker2021humanandviral pages 1-3, bandolasimon2023regulationofmhc pages 1-2)
Membrane-anchored CD86 is the primary functional form, but a human soluble splice variant lacking the transmembrane-encoding exon has also been reported. In the original study, soluble immunoreactive CD86 was detected in 10 of 60 healthy-subject sera; resting monocytes expressed the splice form, and recombinant soluble CD86 bound CD28 and CTLA-4 and costimulated human T cells in culture. This establishes a possible extracellular activity without showing that soluble CD86 is the dominant physiological form or a validated clinical biomarker. Jeannin et al., 2000, DOI: 10.1016/S1074-7613(00)00030-3. (jeannin2000solublecd86is pages 1-2, jeannin2000solublecd86is pages 5-6)
Recent work reinforces the importance of context and cell type, rather than replacing the CD28/CTLA-4 ligand annotation. A 2023 mouse dendritic-cell CRISPR study identified regulators of CD86 surface expression, including Chd4, Stat5b, Egr2 and Med12, as candidates for engineering APC activity; it is not direct evidence that those perturbations work identically in human dendritic cells. Xia et al., Nature Communications, October 2023, DOI: 10.1038/s41467-023-41792-8. (xia2023systematicidentificationof pages 1-3)
In a 2024 mouse model of radiotherapy-treated, lymphocyte-depleted cancer, CD86—but not CD80—blockade curtailed an effector regulatory-T-cell response; adding CD86 blockade to PD-1 blockade improved tumor control in that experimental setting. This is a mechanistically informative preclinical, context-specific result, not evidence that blocking human CD86 generally benefits cancer patients. Frijlink et al., Journal of Clinical Investigation, published February 13, 2024, DOI: 10.1172/JCI171154. (frijlink2024pd1orctla4 pages 1-2)
A separate 2024 translational application exploits CD80/CD86 as recognition cues: investigators observed upregulation of CD80 and/or CD86 in tissue from some patients with relapsed/refractory diffuse large B-cell lymphoma and engineered an experimental anti-CD19 CAR T-cell system with a CTLA-4-based, 4-1BB-containing costimulatory switch. It improved efficacy and selectivity in the reported laboratory and mouse assays, but is not an established clinical treatment, and the findings do not isolate a CD86-only effect. Prinz et al., Cell Reports Medicine, published February 20, 2024, DOI: 10.1016/j.xcrm.2024.101421. (prinz2024ananticd19ctla4switch pages 1-4)
The best-established real-world exploitation of this ligand axis is the use of CTLA-4–Ig proteins, including abatacept in autoimmune disease and belatacept in kidney-transplant immunosuppression: they occupy both CD86 and CD80, limiting access to T-cell CD28. Their clinical effects therefore validate targeting the shared costimulatory pathway, not a CD86-selective intervention. A 2024 authoritative review emphasizes that CD28 costimulation and its competition with CTLA-4 remain central to interpreting cancer immunotherapy; a transplant-focused review describes belatacept’s clinical use and limitations. Lotze et al., 2024, DOI: 10.1038/s41577-024-01061-1; Iglesias et al., Frontiers in Immunology, 2022, DOI: 10.3389/fimmu.2022.926648. (lotze2024cd28costimulationnovel pages 1-3, lankipalli2021crypticassociationof pages 1-2)
Interpretive caution. Published secondary accounts consulted here assign conflicting receptor labels to numerical CD86-binding dissociation constants. Because binding values depend on assay format and receptor valency, this report does not treat either disputed numerical assignment as definitive. The robust annotation is that CD86 binds both CD28 and CTLA-4, and that expression, ligand capture and receptor competition determine whether its presence supports activation or restraint. Similarly, biochemical reverse signaling into CD86-expressing B cells has been demonstrated in a murine in-vitro system, but should not be presented as the established primary function of human CD86. Kennedy et al., 2022, DOI: 10.1038/s41590-022-01289-w; Kin and Sanders, Journal of Immunology, June 2006, DOI: 10.4049/jimmunol.176.11.6727. (girard2006roleofcd80 pages 59-63, kennedy2022differencesincd80 pages 1-2, lankipalli2021crypticassociationof pages 1-2, kin2006cd86stimulationon pages 1-2)
References
(caux1994b70b72isidentical pages 1-2): C. Caux, trice Vanbervliet, C. Massacrier, M. Azuma, K. Okumura, L. Lanier, and J. Banchereau. B70/b7-2 is identical to cd86 and is the major functional ligand for cd28 expressed on human dendritic cells. The Journal of Experimental Medicine, 180:1841-1847, Nov 1994. URL: https://doi.org/10.1084/jem.180.5.1841, doi:10.1084/jem.180.5.1841. This article has 474 citations.
(lankipalli2021crypticassociationof pages 4-5): Swetha Lankipalli, Mahadeva Swamy H S, Deepak Selvam, Dibyendu Samanta, Deepak Nair, and Udupi A. Ramagopal. Cryptic association of
(lankipalli2021crypticassociationof pages 2-4): Swetha Lankipalli, Mahadeva Swamy H S, Deepak Selvam, Dibyendu Samanta, Deepak Nair, and Udupi A. Ramagopal. Cryptic association of
(lankipalli2021crypticassociationof pages 1-2): Swetha Lankipalli, Mahadeva Swamy H S, Deepak Selvam, Dibyendu Samanta, Deepak Nair, and Udupi A. Ramagopal. Cryptic association of
(lotze2024cd28costimulationnovel pages 1-3): Michael T. Lotze, Scott H. Olejniczak, and Dimitris Skokos. Cd28 co-stimulation: novel insights and applications in cancer immunotherapy. Nature reviews. Immunology, 24:878-895, Jul 2024. URL: https://doi.org/10.1038/s41577-024-01061-1, doi:10.1038/s41577-024-01061-1. This article has 100 citations.
(qureshi2011transendocytosisofcd80 pages 2-4): Omar S. Qureshi, Yong Zheng, Kyoko Nakamura, Kesley Attridge, Claire Manzotti, Emily M. Schmidt, Jennifer Baker, Louisa E. Jeffery, Satdip Kaur, Zoe Briggs, Tie Z. Hou, Clare E. Futter, Graham Anderson, Lucy S.K. Walker, and David M. Sansom. Trans-endocytosis of cd80 and cd86: a molecular basis for the cell-extrinsic function of ctla-4. Science, 332:600-603, Apr 2011. URL: https://doi.org/10.1126/science.1202947, doi:10.1126/science.1202947. This article has 2633 citations and is from a highest quality peer-reviewed journal.
(kennedy2022differencesincd80 pages 1-2): Alan Kennedy, Erin Waters, Behzad Rowshanravan, Claudia Hinze, Cayman Williams, Daniel Janman, Thomas A. Fox, Claire Booth, Anne M. Pesenacker, Neil Halliday, Blagoje Soskic, Satdip Kaur, Omar S. Qureshi, Emma C. Morris, Shinji Ikemizu, Christopher Paluch, Jiandong Huo, Simon J. Davis, Emmanuel Boucrot, Lucy S. K. Walker, and David M. Sansom. Differences in cd80 and cd86 transendocytosis reveal cd86 as a key target for ctla-4 immune regulation. Nature Immunology, 23:1365-1378, Aug 2022. URL: https://doi.org/10.1038/s41590-022-01289-w, doi:10.1038/s41590-022-01289-w. This article has 288 citations and is from a highest quality peer-reviewed journal.
(xu2023ctla4depletest pages 2-4): Xiaozheng Xu, Preston Dennett, Jibin Zhang, Alice Sherrard, Yunlong Zhao, Takeya Masubuchi, Jack D. Bui, Xu Chen, and Enfu Hui. Ctla4 depletes t cell endogenous and trogocytosed b7 ligands via cis-endocytosis. The Journal of Experimental Medicine, Apr 2023. URL: https://doi.org/10.1084/jem.20221391, doi:10.1084/jem.20221391. This article has 65 citations.
(xu2023ctla4depletest pages 4-6): Xiaozheng Xu, Preston Dennett, Jibin Zhang, Alice Sherrard, Yunlong Zhao, Takeya Masubuchi, Jack D. Bui, Xu Chen, and Enfu Hui. Ctla4 depletes t cell endogenous and trogocytosed b7 ligands via cis-endocytosis. The Journal of Experimental Medicine, Apr 2023. URL: https://doi.org/10.1084/jem.20221391, doi:10.1084/jem.20221391. This article has 65 citations.
(xu2023ctla4depletest pages 1-2): Xiaozheng Xu, Preston Dennett, Jibin Zhang, Alice Sherrard, Yunlong Zhao, Takeya Masubuchi, Jack D. Bui, Xu Chen, and Enfu Hui. Ctla4 depletes t cell endogenous and trogocytosed b7 ligands via cis-endocytosis. The Journal of Experimental Medicine, Apr 2023. URL: https://doi.org/10.1084/jem.20221391, doi:10.1084/jem.20221391. This article has 65 citations.
(jeannin2000solublecd86is pages 1-2): Pascale Jeannin, Giovanni Magistrelli, Jean-Pierre Aubry, Gersende Caron, Jean-François Gauchat, Toufic Renno, Nathalie Herbault, Liliane Goetsch, Aline Blaecke, Pierre-Yves Dietrich, Jean-Yves Bonnefoy, and Yves Delneste. Soluble cd86 is a costimulatory molecule for human t lymphocytes. Immunity, 13 3:303-12, Sep 2000. URL: https://doi.org/10.1016/s1074-7613(00)00030-3, doi:10.1016/s1074-7613(00)00030-3. This article has 163 citations and is from a highest quality peer-reviewed journal.
(bandolasimon2023regulationofmhc pages 1-2): Joanna Bandola-Simon and Paul A Roche. Regulation of mhc class ii and cd86 expression by march-i in immunity and disease. Jun 2023. URL: https://doi.org/10.1016/j.coi.2023.102325, doi:10.1016/j.coi.2023.102325. This article has 21 citations and is from a peer-reviewed journal.
(trenker2021humanandviral pages 1-3): Raphael Trenker, Xinyu Wu, Julie V. Nguyen, Stephen Wilcox, Alan F. Rubin, Matthew E. Call, and Melissa J. Call. Human and viral membrane–associated e3 ubiquitin ligases march1 and mir2 recognize different features of cd86 to downregulate surface expression. Journal of Biological Chemistry, 297:100900, Jul 2021. URL: https://doi.org/10.1016/j.jbc.2021.100900, doi:10.1016/j.jbc.2021.100900. This article has 16 citations and is from a domain leading peer-reviewed journal.
(jeannin2000solublecd86is pages 5-6): Pascale Jeannin, Giovanni Magistrelli, Jean-Pierre Aubry, Gersende Caron, Jean-François Gauchat, Toufic Renno, Nathalie Herbault, Liliane Goetsch, Aline Blaecke, Pierre-Yves Dietrich, Jean-Yves Bonnefoy, and Yves Delneste. Soluble cd86 is a costimulatory molecule for human t lymphocytes. Immunity, 13 3:303-12, Sep 2000. URL: https://doi.org/10.1016/s1074-7613(00)00030-3, doi:10.1016/s1074-7613(00)00030-3. This article has 163 citations and is from a highest quality peer-reviewed journal.
(xia2023systematicidentificationof pages 1-3): Lei Xia, Anastasia Komissarova, Arielle Jacover, Yehuda Shovman, Sebastian Arcila-Barrera, Sharona Tornovsky-Babeay, Milsee Mol Jaya Prakashan, Abdelmajeed Nasereddin, Inbar Plaschkes, Yuval Nevo, Idit Shiff, Oshri Yosefov-Levi, Tamara Izhiman, Eleonora Medvedev, Elad Eilon, Asaf Wilensky, Simon Yona, and Oren Parnas. Systematic identification of gene combinations to target in innate immune cells to enhance t cell activation. Nature Communications, Oct 2023. URL: https://doi.org/10.1038/s41467-023-41792-8, doi:10.1038/s41467-023-41792-8. This article has 12 citations and is from a highest quality peer-reviewed journal.
(frijlink2024pd1orctla4 pages 1-2): Elselien Frijlink, Douwe M.T. Bosma, Julia Busselaar, Thomas W. Battaglia, Mo D. Staal, Inge Verbrugge, and Jannie Borst. Pd-1 or ctla-4 blockade promotes cd86-driven treg responses upon radiotherapy of lymphocyte-depleted cancer in mice. The Journal of Clinical Investigation, Feb 2024. URL: https://doi.org/10.1172/jci171154, doi:10.1172/jci171154. This article has 38 citations.
(prinz2024ananticd19ctla4switch pages 1-4): Lars Fabian Prinz, Tobias Riet, Daniel Felix Neureuther, Simon Lennartz, Danuta Chrobok, Hanna Hübbe, Gregor Uhl, Nicole Riet, Petra Hofmann, Marianna Hösel, Adrian Georg Simon, Luis Tetenborg, Paul Segbers, Joji Shimono, Philipp Gödel, Hyatt Balke-Want, Ruth Flümann, Gero Knittel, Hans Christian Reinhardt, Christoph Scheid, Reinhard Büttner, Björn Chapuy, Roland Tillmann Ullrich, Michael Hallek, and Markus Martin Chmielewski. An anti-cd19/ctla-4 switch improves efficacy and selectivity of car t cells targeting cd80/86-upregulated dlbcl. Cell Reports Medicine, 5:101421, Feb 2024. URL: https://doi.org/10.1016/j.xcrm.2024.101421, doi:10.1016/j.xcrm.2024.101421. This article has 24 citations and is from a peer-reviewed journal.
(girard2006roleofcd80 pages 59-63): T Girard. Role of cd80 and cd86 cosignaling proteins functional domains in molecular structure and adaptive immune responses. Unknown journal, 2006.
(kin2006cd86stimulationon pages 1-2): Nicholas W. Kin and Virginia M. Sanders. Cd86 stimulation on a b cell activates the phosphatidylinositol 3-kinase/akt and phospholipase cγ2/protein kinase cαβ signaling pathways1. The Journal of Immunology, 176:6727-6735, Jun 2006. URL: https://doi.org/10.4049/jimmunol.176.11.6727, doi:10.4049/jimmunol.176.11.6727. This article has 43 citations.